# Phase 4 obesity trials recruiting: 87 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 87 trials in phase 4 for obesity that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 4 obesity trials: 87 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 7 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-4/obesity

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 87
- Recruiting or not yet: 87
- Read on: November 19, 2026

## Trials

The 25 newest of 87, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07900074 | Mechanisms of Weight Loss: Tirzepatide vs Semaglutide | McMaster University | Phase 4 | Recruiting | Obesity (Disorder) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900074) |
| October 26, 2026 | NCT07893457 | Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity | Mayo Clinic | Phase 4 | Not yet recruiting | Obese Adults | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07893457) |
| October 14, 2026 | NCT07872904 | FutureShape Family | Sponsor not shown (see the record) | Phase 4 | Recruiting | Obesity, Overweight | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07872904) |
| October 13, 2026 | NCT07870538 | A Neuropsychobiological Approach to Optimize Patient Selection for GLP-1-based Pharmacotherapy for Weight Management Across the Binge... | Universitaire Ziekenhuizen KU Leuven | Phase 4 | Recruiting | Obesity & Overweight | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07870538) |
| October 9, 2026 | NCT07868471 | Community Active and Healthy Families Pragmatic Trial | University of Colorado, Denver | Phase 4 | Not yet recruiting | Child Obesity | 416 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868471) |
| October 5, 2026 | NCT07859189 | Immediate Versus Criterion-triggered Semaglutide for Suboptimal Clinical Response One Year After Primary Metabolic and Bariatric Surgery | General Committee of Teaching Hospitals and Institutes, Egypt | Phase 4 | Not yet recruiting | Morbid Obesity | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859189) |
| October 5, 2026 | NCT07859176 | Tapered Versus Abrupt Discontinuation of Semaglutide After Treatment of Recurrent Weight Gain or Suboptimal Response Following Metabolic... | General Committee of Teaching Hospitals and Institutes, Egypt | Phase 4 | Not yet recruiting | Morbid Obesity | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859176) |
| October 5, 2026 | NCT07859163 | Semaglutide Given Before and After Conversion of Sleeve Gastrectomy to Roux-en-Y Gastric Bypass for Recurrent Weight Gain | General Committee of Teaching Hospitals and Institutes, Egypt | Phase 4 | Not yet recruiting | Morbid Obesity | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859163) |
| October 5, 2026 | NCT07859150 | Semaglutide 2.4 mg Once Weekly for Recurrent Weight Gain After Metabolic and Bariatric Surgery (RESURGE) | General Committee of Teaching Hospitals and Institutes, Egypt | Phase 4 | Not yet recruiting | Morbid Obesity | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859150) |
| October 5, 2026 | NCT07859137 | Semaglutide Before Primary Metabolic and Bariatric Surgery in Patients With BMI 60 kg/m² or Higher | General Committee of Teaching Hospitals and Institutes, Egypt | Phase 4 | Not yet recruiting | Morbid Obesity | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07859137) |
| October 5, 2026 | NCT07858331 | Patient-centred Intervention With Virtual Support for Obesity and Kidney Transplant Access | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Obesity, Chronic Kidney Disease, Chronic Renal Disease, CKD | 880 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07858331) |
| October 1, 2026 | NCT07850960 | Effect of Omeprazole on Gut Microbiota in Adults With Obesity and GERD | Federal State Budgetary Scientific Institution | Phase 4 | Not yet recruiting | Obesity & Overweight, Gastroesophageal Reflux Disease | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850960) |
| September 30, 2026 | NCT07850466 | TRPTI Metabolic and GLP-1 Pharmacodynamic Study | RDC Clinical Pty Ltd | Phase 4 | Not yet recruiting | Overweight , Obesity | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07850466) |
| September 21, 2026 | NCT07832084 | Comparing Different Medication Regimens to Maintaining Weight Loss Among Adults With Obesity Using GLP-1s | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Obesity & Overweight, Cardiometabolic Health Indicators | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832084) |
| September 17, 2026 | NCT07824895 | Mazdutide for Weight Management and Gout in Adults With Obesity | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Gout, Obesity (BMI\>30), Hyperuricemia, Metabolic Syndrome | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07824895) |
| August 25, 2026 | NCT07783854 | A Randomized Controlled Study of Dose-tapering Regimen of Semaglutide for Weight-Loss Maintenance in Adults With Overweight or Obesity | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Phase 4 | Not yet recruiting | Obesity & Overweight | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07783854) |
| August 20, 2026 | NCT07777575 | Resistance Training to Prevent Muscle Loss During Treatment With Tirzepatide | Technical University of Munich | Phase 4 | Recruiting | Obesity (BMI\>30) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07777575) |
| August 18, 2026 | NCT07770152 | Semaglutide in Youth With Autism Spectrum Disorder | Children's Hospital Medical Center, Cincinnati | Phase 4 | Recruiting | Autism Spectrum Disorder, Obesity | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07770152) |
| August 12, 2026 | NCT07759778 | Oliceridine-Propofol Dose for Gastroscope Insertion in Obese Patients | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Obesity, Gastrointestinal Endoscopy | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07759778) |
| August 10, 2026 | NCT07755085 | GLP-1s in Hip and Knee Arthroplasty | Nova Scotia Health Authority | Phase 4 | Not yet recruiting | Arthritis, Obesity & Overweight, GLP - 1 | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07755085) |
| August 5, 2026 | NCT07748247 | Swap Anesthetic Versus Continuous Desflurane in Adults Undergoing Bariatric Surgery | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Obesity, Bariatric Surgery | 82 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07748247) |
| July 27, 2026 | NCT07729332 | Switching to Oral Weight Management Pharmacotherapy to Prevent Weight Regain After GLP-1 Therapy Discontinuation | Massachusetts General Hospital | Phase 4 | Not yet recruiting | Obesity | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07729332) |
| July 27, 2026 | NCT07728383 | A Proof-of-Concept Study to Evaluate Topical-Lingual Semaglutide in Adults With Obesity | Gila Therapeutics, Inc. | Phase 4 | Recruiting | Obesity & Overweight | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07728383) |
| July 21, 2026 | NCT07715929 | Effect of Tirzepatide on Recurrence of Atrial Fibrillation After Catheter Ablation in Obese Patients | Sponsor not shown (see the record) | Phase 4 | Not yet recruiting | Atrial Fibrillation, Obesity & Overweight, Catheter Ablation | 710 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715929) |
| July 13, 2026 | NCT07699445 | The Effects of Lumateperone on Obesity and Physiologic Aging and Their Association With Antidepressant Response in Bipolar Depression | Massachusetts General Hospital | Phase 4 | Recruiting | Bipolar Depression Depressed Phase, Obesity & Overweight | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07699445) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| General Committee of Teaching Hospitals and Institutes, Egypt | 5 |
| Mayo Clinic | 4 |
| University of Colorado, Denver | 3 |
| Columbia University | 2 |
| Massachusetts General Hospital | 2 |
| The Cleveland Clinic | 2 |
| McMaster University | 2 |
| Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| Peking University Third Hospital | 1 |
| The First Affiliated Hospital of Anhui Medical University | 1 |
| The Royal's Institute of Mental Health Research | 1 |
| University Medical Center, Kazakhstan | 1 |
| University of Missouri-Columbia | 1 |
| University Medical Centre Ljubljana | 1 |
| University of California, Irvine | 1 |
| Federal State Budgetary Scientific Institution | 1 |
| Hospital Universitario Dr. Jose E. Gonzalez | 1 |
| Las Rías Medical Center | 1 |
| China National Center for Cardiovascular Diseases | 1 |
| William Marsh Rice University | 1 |
| Huazhong University of Science and Technology | 1 |
| Weill Medical College of Cornell University | 1 |
| University Hospital, Tours | 1 |
| Korea University Anam Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 26 |
| China | 10 |
| Canada | 10 |
| Egypt | 5 |
| Pakistan | 3 |
| Sweden | 2 |
| Mexico | 2 |
| Finland | 2 |
| India | 2 |
| Ireland | 2 |
| Kuwait | 2 |
| Spain | 2 |
| Switzerland | 2 |
| United Kingdom | 2 |
| Denmark | 2 |
| Germany | 2 |
| Kazakhstan | 1 |
| Austria | 1 |
| Russia | 1 |
| Paraguay | 1 |
| Brazil | 1 |
| Italy | 1 |
| France | 1 |
| South Korea | 1 |
| Australia | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Nursing schools in the United States](https://specstream.ai/data/businesses/nursing-schools/united-states)
- [Auto lenders in the United States](https://specstream.ai/data/businesses/auto-lenders/united-states)
- [Hospital equipment suppliers in the United States](https://specstream.ai/data/businesses/hospital-equipment-suppliers/united-states)
- [Taco restaurants in the United States](https://specstream.ai/data/businesses/taco-restaurants/united-states)
- [Drive thru bars in the United States](https://specstream.ai/data/businesses/drive-thru-bars/united-states)
- [Pharmaceutical products wholesalers in the United States](https://specstream.ai/data/businesses/pharmaceutical-products-wholesalers/united-states)
